SIRT6 and neoplasm: Derivatives of Quinazolinedione were recently discovered to inhibit Sirt6 activity, and these compounds were seen to sensitise the tumour cells to chemotherapeutic agents (Sociali et al., 2015; Rahnasto-Rilla et al., 2018).